Norethindrone Acetate And Ethinyl Estradiol Tablet
Product Images NDC 68462-656

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Norethindrone Acetate And Ethinyl Estradiol (NDC 68462-656). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Glenmark Pharmaceuticals Inc., Usa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ctn 0 5mg 2 5mcg

Packaging label for Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 0.5 mg/2.5 mcg, by Glenmark Pharmaceuticals Inc. The label shows the product name and strength prominently with purple accents on a beige background with decorative patterns. It states the package contains 3 pouches, each with a blister of 28 tablets, and includes storage instructions, manufacturer information, and a barcode.*

FDA Label Image

Ctn 1mg 5mcg

Packaging label for Norethindrone Acetate and Ethinyl Estradiol Tablets, USP, 1 mg/5 mcg, oral tablets. The label displays the drug name and strength prominently on a light beige background with blue panels on the sides and bottom. It notes the carton contains 3 pouches, each with 1 blister of 28 tablets. Manufactured by Glenmark Pharmaceuticals Inc., USA.*

FDA Label Image

Eestructure.jpg (Ethinylestradiol)

Chemical structure of Norethindrone Acetate and Ethinyl Estradiol showing the molecular arrangement of the active ingredients in this oral tablet formulation by Glenmark Pharmaceuticals Inc.*

FDA Label Image

Noreestructure.jpg (Norethindroneacetate)

Chemical structure of Norethindrone Acetate and Ethinyl Estradiol depicted in a structural formula diagram with labeled atoms and bonds representing the steroid framework and functional groups.*

FDA Label Image

Fig1.jpg (Femhrt Tablets 3)

Two line graphs depicting mean plasma concentrations over time up to 24 hours. The top graph shows mean plasma norethindrone concentration in ng/mL, rising quickly to a peak near 10 ng/mL then gradually declining. The bottom graph shows mean plasma ethinyl estradiol concentration in pg/mL, peaking around 36 pg/mL before a gradual decrease. Time in hours is on the x-axis for both graphs.*

FDA Label Image

Fig2.jpg (Figure 2)

A line graph displaying the percentage of patients over a 12-month period across four groups: Placebo, Norethindrone Acetate/Ethinyl Estradiol 0.5 mg/2.5 mcg, and Norethindrone Acetate/Ethinyl Estradiol 1 mg/5 mcg. The x-axis represents months of treatment, and the y-axis shows the percentage of patients, with plotted lines indicating increasing patient percentages over time for each group.*

FDA Label Image

Fig3.jpg (Figure 3)

A bar chart illustrating mean percentage change at 12 and 24 months for three groups: placebo, Norethindrone Acetate and Ethinyl Estradiol (NA/EE) 0.5 mg/2.5 mcg, and NA/EE 1 mg/5 mcg. Bars show increasing positive change for active treatment groups compared to negative or less change in placebo. Error bars indicate variability, with statistical significance noted for treatment groups versus placebo.*

FDA Label Image

Logo.jpg (Image 01)

FDA Label Image

Logo.jpg (Logo)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.